Why the study?
Does low molecular weight heparin compared to un-fractionated heparin improve economic viability in the treatment of acute deep vein thrombosis?
Population
80 patients with acute deep vein thrombosis (ADVT)
Comparison
Low molecular weight heparin followed by oral… vs Continuous infusion un-fractionated heparin…
Design
Cohort
Authors
Loading...
Supports the cost-effectiveness of LMWH for acute DVT without compromising safety.
Does low molecular weight heparin compared to un-fractionated heparin improve economic viability in the treatment of acute deep vein thrombosis?
Switching from continuous un-fractionated heparin to low molecular weight heparin for acute DVT treatment is economically viable.
Haris Vukas (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: